Company
T-CURX is a spin-out from the University Clinics Würzburg, Germany, co-founded by Prof. Michael Hudecek (MD), University Clinics Würzburg, Germany, Prof. Christoph Rader (PhD), University of Florida, U.S., and Dr. Ulf Grawunder (PhD), Switzerland. The founders aim at building a leading European CAR-T cell company.
For this ambition, T-CURX is leveraging proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, focussing on novel cancer targets based on Prof. Rader’s research. This cutting-edge research will boost the development of first- and best-in-class CAR-T cell product opportunities for both hematological and solid cancer indications. The commercial translation of T-CURX’ transformative CAR-T technologies and CAR-T cell products is led by T-CURX’ experienced leadership team headed by Ulf Grawunder as CEO. T-CURX' development is also supported by scientific key opinion leaders and Biotech-industry veterans with proven track records in developing innovative medicines in the fields of immunology and cancer.
T-CURX is partner in a number of international consortia and projects, in which personalized, cellular immunotherapies are developed, including the Horizon-2020 EU translational project CARAMBA. This project has translated CS1/SLAM-F7 CAR-T cells into phase 1 clinical trials by utilizing T-CURX’ virus-free, transposon-based CAR-T technology in multiple myeloma.
Partners and Business Development
Partners and Business Development